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1. Introduction  
Diabetes mellitus is a leading cause of mortality, morbidity, and health care costs among 
beneficiaries of the U.S. Medicare program. Serious and costly complications of diabetes 
include vision loss, kidney failure, nerve damage, coronary artery disease, cerebro-vascular 
disease, peripheral vascular disease, foot ulcers, lower extremity amputations, and 
infections. These complications often can be avoided through case management, monitoring, 
control of risk factors, and self-care (American Diabetes Association, n.d.[a], n.d.[b]). 
Unfortunately, geographic, linguistic, or cultural isolation keeps many Medicare 
beneficiaries from obtaining high-quality diabetes care. Isolation also may lessen 
beneficiaries’ motivation to eat appropriately, exercise, and lose weight as advised by a 
physician. Beneficiaries most likely to suffer from diabetes and its complications, including 
those of African or Hispanic/Latino descent, also may be prone to isolation (Health 
Resources and Services Administation., n.d.). 
Home telemedicine is the use of telecommunications technology to deliver diagnostic, 
monitoring, educational, and therapeutic services to health care users in their own homes. It 
may be a promising way to deliver such services to people living in medically underserved 
areas. Little is known about how well home telemedicine works for Medicare beneficiaries. 
A congressionally mandated demonstration tested the clinical and cost outcomes of 
providing a particular type of home telemedicine service to a large number of Medicare 
beneficiaries who have diabetes and live in medically underserved areas of New York City 
and upstate New York. A consortium led by Columbia University College of Physicians and 
Surgeons and Columbia-Presbyterian Medical Center (the Consortium) performed the 
demonstration, which it called Informatics for Diabetes Education and Telemedicine, or 
IDEATel. Mathematica Policy Research was the independent evaluator. The Centers for 
Medicare & Medicaid Services (CMS) funded and oversaw the demonstration and 
evaluation. The demonstration was implemented in two four-year phases, from February 
2000 to February 2008. Beneficiary enrollment began in December 2000. 
Principal investigators for the Consortium have published results of their own analyses of 
the final effects of IDEATel on key clinical outcomes and costs (Shea et al., 2009); (Palmas et 
al., 2010). As in the independent evaluation (Moreno et al., 2009; Moreno et al., 2008), they 
found that the intervention positively affected participants’ blood sugar, blood pressure, 
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and lipid levels. These effects, however, must be considered in light of the intervention’s 
acceptability to beneficiaries and potential cost savings to Medicare.  
This chapter summarizes (1) participants’ use of the telemedicine technology, (2) 
intervention effects on intermediate clinical outcomes, (3) intervention effects on the use and 
cost of Medicare services, and (4) costs of the demonstration during the two phases. It also 
discusses the policy implications of these findings in the context of recent U.S. health 
reform, particularly the potential role of home telemedicine in the Medicare program. 
2. Demonstration overview 
2.1 Goals  
IDEATel’s goals for participants were to (1) control blood sugar, high blood pressure, and 
abnormal lipid levels; and (2) reduce or eliminate obesity and physical inactivity. To help 
participants meet these goals, the Consortium designed an intervention to provide remote 
monitoring, case management, and web-based educational materials through a home 
telemedicine unit (HTU). IDEATel’s goal for physicians was to increase provision of 
guideline-based diabetes care. To help physicians meet this goal, IDEATel diabetologists 
recommended guideline-based treatment adjustments when they believed changes were 
warranted. The Consortium also designed a web-based physician curriculum (Figure 1). 
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Source:  Synthesis from Columbia University (1998) and other unpublished demonstration materials. 
a WebCIS access only available in New York City.  
b Email reminders were not systematically implemented in upstate New York.  
c Chat rooms were not implemented in either site.  
WebCIS = Clinical Information System, Columbia-Presbyterian Medical Center, New York. 
Fig. 1. The IDEATel System Intervention 
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2.2 Recruitment 
The Consortium first recruited primary care physicians in the demonstration target areas. 
Consenting physicians furnished lists of their Medicare patients to the Consortium, which 
screened patients for eligibility and attempted to recruit those who were eligible. Between 
December 2000 and October 2002, the demonstration recruited 1,665 eligible Medicare 
beneficiaries (775 in New York City and 890 in upstate New York) for Cohort 1 and 
randomly assigned them, in equal proportions, to a treatment or control group (Table 1). 
Between December 2004 and October 2005, the demonstration recruited 504 eligible 
Medicare beneficiaries (174 in New York City and 330 in upstate New York) for Cohort 2 
and randomly assigned them to a treatment or a control group.  
 
 Site  
Evaluation Group/Cohort New York City Upstate New York Total 
Cohort 1    
Treatment 397 447 844 
Control 378 443 821 
Total 775 890 1,665 
    
Cohort 2    
Treatment 86 163 249 
Control 88 167 255 
Total 174 330 504 
Source:  IDEATel tracking-status file (Columbia University, 2007a). 
Table 1. Distribution of Enrollees, by Site and Evaluation Group 
Eligibility was limited to English- or Spanish-speaking Medicare beneficiaries age 55 or 
older who were being treated for diabetes by diet, oral medications, or insulin, and were 
living in a medically underserved or health professional shortage area in New York State. 
Beneficiaries with moderate or severe cognitive, visual, or physical impairment or with 
severe comorbid disease were excluded. Neither literacy nor prior computer experience 
were grounds for inclusion or exclusion. Consenting beneficiaries underwent a 
comprehensive in-person baseline assessment by Consortium staff that included a 
structured interview; measurements of body dimensions, weight, and blood pressure; blood 
and urine tests; and setup of a 24-hour ambulatory blood pressure monitor. The Consortium 
randomly assigned beneficiaries, in equal proportions, to a treatment or control group and 
sent laboratory results from the baseline assessments to the enrollees‘ physicians.   
2.3 The Intervention  
During the demonstration, control group members received diabetes care as usual from 
their primary care physicians. Treatment group participants also continued to see their 
primary care physicians, and they received a HTU. (Enrollees are eligible Medicare 
beneficiaries enrolled in the demonstration.  Participants are enrollees in the treatment 
group, regardless of whether they received the intervention and used the services offered.) 
For Phase I of the demonstration, the HTU (Generation 1) consisted of a personal computer 
with audio/video communication capabilities and devices for measuring blood sugar and 
blood pressure (Figure 2, right panel). For Phase II, the Consortium redesigned the HTU to 
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address several features that Cohort 1 participants had found unappealing, such as its large 
size and difficulty of use. The redesigned HTU (Figure 2, left panel) is known as Generation 
2 or Generation 3, depending on the manufacturing date. The Generation 3 HTU had several 
advantages, such as a cast aluminum case, higher screen resolution, and smaller “footprint,” 
that is, the table area it occupied (Columbia University, 2005). 
Demonstration participants could use the HTU:  
• To measure and monitor blood pressure and blood sugar and transmit their 
measurements to a nurse case manager; readings were stored in the HTU until 
participants performed an upload of the data (Generation 1 HTU) or the HTU 
transmitted them through periodic automatic uploads (Generation 2 and 3 HTUs) 
• To communicate with a nurse case manager through audio/videoconferences known as 
“televisits” 
• To access web-based chat rooms and educational materials available only to 
participants: chat rooms were implemented in both sites; Email reminders were not 
systematically implemented in the upstate site; and WebCIS access was operational 
only in New York City (U.S. Department of Health and Human Services, 2005). 
 
           
                                      Generation 2                                                 Generation 1 
Source: Foster et al. (2006). 
Fig. 2. The Generation 2 HTU and Its Predecessor 
Televisits were a major component of the IDEATel intervention. By providing regular 
interaction between participants and nurse case managers at workstations in New York City 
or Syracuse, they were expected to help participants learn more about diabetes and self-care, 
improve their attitude toward their disease, and change their behavior. Televisits were to 
occur every two weeks, be scheduled in advance, and last about 30 minutes each. 
2.4 Intended effects  
Nurse education and coaching through televisits and self-tracking of progress through other 
HTU functions were expected to improve self-care behaviors such as monitoring blood 
sugar and blood pressure, and adhering to diet, exercise, foot care, and medication regimes. 
By giving physicians guideline-based recommendations, IDEATel also aimed to promote 
better prescribing patterns, which could improve physiologic outcomes. Better blood sugar 
control, weight loss, and improved fitness might help participants feel better in the short 
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run. Improved control of blood sugar, lipids, blood pressure, weight loss, and improved 
fitness might help them avoid serious complications such as blindness, kidney failure, 
stroke, heart disease, and lower extremity infections and amputations in the long run. Better 
health, in turn, could reduce use of acute care services and Medicare costs. 
3. Related research 
Published studies of programs that use remote monitoring and web-based education to 
manage diabetes have generally used much smaller samples than IDEATel and have not 
focused on the Medicare population. Nonetheless, some diabetes management programs 
have demonstrated clinical effectiveness with relatively simple interventions. Aubert et al. 
(1998), The California Medi-Cal Type 2 Diabetes Study Group (2004), and Taylor et al. (2003) 
have used randomized experiments to test the clinical effects of providing nurse case 
management services to patients by telephone. All three of the tested interventions 
favorably affected hemoglobin A1c levels.  
Other researchers have tested the effects of automated telephone systems on diabetes 
control. Piette et al. (2000) performed a randomized study of a computer system that called 
enrollees and asked questions in a recorded human voice. Enrollees responded by 
depressing buttons on a regular touch-tone telephone, prompting appropriate follow-up 
questions (Piette, 2000). Significant positive effects were found on self-reported self-care, 
self-efficacy, days of disability, communication with health care providers, and hemoglobin 
A1c. Delichatsios et al. (2001) found favorable effects on blood sugar control and satisfaction 
in a nonrandomized study of a similar intervention. Finally, several small studies of 
interventions featuring simple glucometers that allowed patients to record blood sugar 
measurements and upload them through a telephone modem showed favorable effects on 
diabetes-related behaviors and hemoglobin A1c (Ahring et al., 1992; Meneghini et al, 1998; 
Shultz et al., 1992). 
Although not formally evaluated, many relatively inexpensive home telemedicine products 
are commercially available. Like the IDEATel HTU, such units use regular telephone lines 
and feature two-way videoconferencing, glucometers, blood pressure cuffs, and store-and-
forward capability. Unlike the IDEATel HTU, however, these units are not PC-based, do not 
use the Internet, and do not allow for web browsing, electronic messaging, or software for 
tracking personal progress in diet, weight loss, or exercise (AmericanTeleCare, n.d.; 
HomMed, n.d.). 
Few studies provide evidence about costs or both costs and clinical effectiveness. In 2004 the 
Congressional Budget Office (CBO) examined peer-reviewed studies for evidence of the 
cost-effectiveness of disease management in treating chronic illness (Congressional Budget 
Office, 2004). Thirty-one of the studies targeted diabetes and many featured telemedicine or 
another form of remote monitoring. Although many programs favorably affected process of 
care and intermediate outcomes, few studies measured effects on long-term health 
outcomes, health care use, and costs. Those attempting to address costs failed to account for 
the costs of the interventions themselves. Around the time of the CBO review, however, 
Villagra and Ahmed published the first-year results of a multistate diabetes management 
program sponsored by CIGNA HealthCare (Villagra & Ahmed, 2004). The intervention used 
telephone outreach by nurses, dietitians, or health educators; web-based education; remote 
monitoring devices; and mailed reminders and educational materials. Using two quasi-
experimental methods, investigators found that, among members observed for at least 10 
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months, the intervention reduced overall health care costs by 8 to 25 percent per member 
per month (based on claims and encounter data), depending on the analytic method. 
Although these savings purportedly exceeded the cost of the intervention under both 
analytic methods, intervention costs were not reported. Moreover, since only 7 percent of 
the CIGNA subjects were age 65 or older, relevance to the Medicare program and 
comparability to IDEATel are limited.  
4. Study methods 
Mathematica researchers collected information through case studies of the IDEATel 
demonstration, including Consortium leadership and staff, participating physicians, and 
treatment group enrollees. The evaluation also drew on (1) annual, in-person surveys of 
treatment and control group enrollees; (2) log-use data of the interactions of participants 
with their HTUs; and (3) Medicare enrollment and claims data, all of which were collected 
by the Consortium. Table 2 summarizes the major features of the analysis. 
 
Comparison Key Measures Used Primary Data Sources 
Implementation 
analysis 
Whether IDEATel was 
implemented as Congress 
intended 
- Periodic site visits and telephone 
discussions with Consortium 
leadership and staff, participating 
physicians, and participantsa 
- Demonstration documentation 
Analysis of HTU 
- Frequency of use of specific 
HTU functions and patterns of 
use over time across cohorts 
HTU-use log datab 
Impacts on 
behavioral, 
physiologic, and 
other health-
related outcomes 
- Enrollees’ self-reported: 
communication with providers 
and behavior 
- Selected clinical and laboratory 
outcomes 
- Enrollees’ health-related 
quality of life, and satisfaction 
with diabetes care 
Annual, in-person survey datab 
Impacts on use of 
Medicare-covered 
services and costs 
- Medicare-covered service use 
- Medicare expenditures 
- Costs of implementing the 
demonstration 
Medicare claims datab 
Demonstration documentation 
Source:  Columbia University (2007a, 2007b, 2007c, 2007d). 
aMathematica selected samples of physicians and participants who had consented to be interviewed 
from lists prepared by the Consortium following its IRB’s guidelines.  
bTo ensure confidentiality, the Consortium collected these data and shared them with Mathematica 
without individual-level identifiers. The evaluation used Medicare Part A and Part B claims data; Part D 
had not yet been implemented during the period covered here. 
Table 2. Analytic Approach Summary 
The analyses were conducted separately for the New York City and upstate sites for two 
main reasons. First, some aspects of the intervention implementation at the sites were quite 
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different. Specifically, the upstate intervention team solicited referring physicians’ advance 
permission to adjust participants’ diabetes treatment (for example, medication dosage), 
whereas the New York City team made recommendations to physicians and asked 
participants whether its suggestion was implemented. Second, enrollees from each site 
differed markedly on many major characteristics. 
4.1 Qualitative description of the intervention implementation 
To assess implementation of the demonstration, the analysis synthesized information from 
site visits, telephone calls, and demonstration documentation (U.S. Department of Health 
and Human Services, 2003, 2005). Site visits and telephone discussions with Consortium 
leadership and staff took place during fall/winter 2001, fall 2002, fall 2003, winter 2005, and 
winter 2007. The interviews with participating physicians and treatment group enrollees 
took place in winter 2007 (Foster et al., 2008). 
4.2 Estimation of HTU use 
To assess participants‘ interactions with the HTU, the analysis examined the time between 
home installation of the HTU and its first use, frequency of use, and patterns of use over 
time from log-use data. It also compared the experiences of Cohort 1 and Cohort 2 
participants in the first two years after the start of HTU installation for each phase 
(December 2000 through February 2007 for Cohort 1 and December 2004 through February 
2007 for Cohort 2), controlling for standard baseline characteristics. The analysis sample 
consisted of 753 Cohort 1 participants (out of 844) and 230 Cohort 2 participants (out of 249). 
For Cohort 1, the analysis excluded 50 participants whose records had a missing installation 
date, 6 who had dropped out before their HTUs were installed, 29 whose records did not 
specify the type of HTU they had received, and 6 whose records did not indicate when their 
HTU was upgraded from Generation 1 to Generation 2. For Cohort 2, the analysis excluded 
17 participants whose installation date was missing and 2 whose records did not specify the 
type of HTU they had received. 
4.3 Estimation of intervention effects 
To assess impacts of the intervention on behavioral, physiologic, and other health-related 
outcomes, the analysis compared outcomes of treatment and control group enrollees using 
regression models that controlled for the baseline characteristics and baseline values for the 
outcomes in question. This analysis used the longitudinal survey data collected at baseline 
and at up to four follow-up annual interviews conducted for Cohort 1 through February 
2007, the end of demonstration operations. Likewise, the analysis used the baseline and first 
annual interviews conducted through February 2007 for Cohort 2.  
To assess impacts of the intervention on the use of Medicare-covered services and costs, the 
analysis compared outcomes of treatment and control group enrollees using regression 
models similar to those described above. This analysis used Medicare enrollment and claims 
data from 1999 through 2006. 
In both the behavioral, physiologic, and health analyses; and the Medicare service use and 
cost analyses, enrollees were analyzed in the group to which they were originally 
randomized (in other words, these were intent-to-treat analyses). However, enrollees who 
dropped out of the study could not be included in the behavioral, physiologic, and health 
analyses for time points after the times they left the study, since they had no further survey 
www.intechopen.com
 Advances in Telemedicine: Technologies, Enabling Factors and Scenarios 
 
326 
and laboratory data. All randomized enrollees were included in the Medicare service use 
and cost analyses since Medicare claims data were available whether or not they had 
dropped out. 
Finally, to assess the costs of the demonstration implementation, the analysis synthesized 
information from demonstration documents and market prices of products and services 
used in the demonstration, according to a methodology developed for the Phase I analysis 
(Starren et al., 2002;U.S. Department of Health and Human Services, 2005).  
4.4 Sample characteristics 
At baseline, Cohort 1 enrollees in the two sites differed in several ways. Compared with 
enrollees in the upstate site, New York City enrollees were more likely to be low-income, 
nonwhite, and Spanish-speaking (as opposed to English-speaking). New York City enrollees 
had fewer years of education than upstate enrollees and were less likely to have ever used a 
personal computer at baseline. In both sites, the treatment and control groups were similar 
on all characteristics, as expected with random assignment (U.S. Department of Health and 
Human Services, 2005).   
In both sites, Cohort 1 and Cohort 2 enrollees differed in several ways. In New York City, 
Cohort 2 enrollees were younger, more likely to be Hispanic, less likely to have formal 
education, and less likely to have had prior experience with personal computers than 
Cohort 1 enrollees. In upstate New York, Cohort 2 enrollees were younger, but more likely 
to have had prior personal computer experience than Cohort 1 enrollees. In both sites, 
however, the Cohort 2 treatment and control groups were similar on all characteristics. 
4.5 Enrollee attrition 
By the fourth year of follow-up interviews, Cohort 1 sample sizes for health outcomes 
analyses declined substantially in both sites. The overall dropout rates in Cohort 1 were 30 
percent in New York City and 58 percent upstate. As discussed in Section 5.3, the loss of 
these sample members substantially decreased the evaluation’s ability to detect impacts. 
Loss of sample size also compromised the statistical power of the Cohort 2 analyses. After 
one year of follow-up interviews, the Cohort 2 attrition rate was 13 percent in New York 
City and 19 percent upstate. As with Cohort 1, however, numbers relative to the original 
sample were small, and there were no great differences between treatment and control 
dropouts in baseline characteristics. 
Reasons for dropping out differed between treatment and control groups. There was a 
somewhat higher dropout rate among the treatment groups (33 percent in New York City, 
64 percent in upstate New York) than the control groups (28 and 52 percent, respectively). In 
the New York City site, the rates of dropout in the treatment group because of death and 
“no reason recorded” were lower than in the control group, whereas the rates for “other 
reason” and, of course, HTU problems, were higher than in the control group. Although 
bias in the estimated impacts due to differences between treatment and control group 
enrollees who dropped out is unknowable, the potential for bias may be mitigated by the 
small numbers in any given category of reason for dropping out relative to the original 
sample size. Treatment and control group members also dropped out for different reasons 
in upstate New York. As in New York City, the rate of dropout in the treatment group 
because of death was lower than in the control group, while the rates of dropout for enrollee 
refusal and “too sick” were higher. But again, the numbers for individual reasons are small 
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relative to the original sample. Finally, the intention-to-treat impact estimates based on 
Medicare claims data are not affected by differential dropout, since claims data are available 
for all enrollees whether or not they remained in the demonstration. 
To assess further the possible effects of attrition on the estimates of program effects on 
health outcomes, the analysis compared the baseline characteristics of those who dropped 
out in Cohort 1 and those who remained. The analysis also assessed the sensitivity of a 
selected set of the calculated year 4 impacts to a range of favorable and unfavorable imputed 
outcome values for Cohort 1 enrollees who dropped out of the treatment or control groups. 
These comparisons and sensitivity analyses did not reveal major differences between 
treatment and control group members who dropped out, or indicate that results were 
sensitive to even extreme assumptions about the missing outcome values.   
4.6 Limitations 
Our evaluation has three main limitations. First, the demonstration was not designed to 
provide evidence on the marginal benefit of the intervention’s components—use of the HTU 
and interactions with the nurse case managers. Thus, the evaluation cannot determine 
whether the clinical impacts of the demonstration resulted from the telemedicine 
intervention, the intensive nurse case management, or both (U.S. Department of Health and 
Human Services, 2005). Second, the high attrition rate in both sites limited any conclusions 
from the survey and in-person data. For instance, the high attrition rate in the upstate site 
between baseline and year 4 raises the possibility of bias of unknown magnitude and 
direction in the estimated impacts. The loss of sample in the New York City site also greatly 
reduced the evaluation’s statistical power to detect impacts there. Finally, for Cohort 1, data 
on the fifth and sixth follow-up annual interviews were not available for enrollees whose 
annual interview data had not come up by the end of the study period (that is, February 27, 
2007). Therefore, the analysis did not include these data. For Cohort 2, data on the second 
follow-up interview were available only for a small number of enrollees. As a result, the 
analysis did not use data from this round of in-person interviews. 
5. Findings 
5.1 IDEATel implementation 
The IDEATel demonstration met requirements established by Congress for implementation. 
However, the intervention as delivered was neither as intensive nor as technologically 
sophisticated as originally designed, since the Consortium encountered unexpected 
challenges and deliberately departed from its plans in some areas. For example, it 
abandoned its intent to hold televisits every two weeks with all participants, as 
demonstration leadership argued that the nurse case managers should determine the 
appropriate frequency for each participant in their caseload. Likewise, the Consortium 
disavowed the premise that use of advanced HTU functions was central to the intervention, 
as leadership revised their hypotheses about the connection between these functions and 
participants’ well-being and motivation to self-care. The most important unplanned 
departure resulted from the inability of a key subcontractor to deliver Generation 2 or 3 
HTUs to most participants, which meant that only a few participants were able to 
experience the planned Phase II technological improvements in the newer units. 
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5.2 HTU use 
Demonstration participants’ use of the HTU was key for the success of the intervention. 
Because the intervention hinged entirely on the use of the HTU, participants who took a 
long time to learn to use the device, or used it infrequently, received correspondingly less 
intervention. To examine the intensity of the intervention and how it varied with length of 
time in the demonstration and across cohorts, the analysis examined use data recorded by 
participants during their interactions with the HTU. 
5.2.1 HTU design, implementation, changes, and problems 
5.2.1.1 Initial HTU design 
During Phase I, The Consortium had difficulty engaging the participants in HTU use. Many 
participants had difficulty connecting to televisits. To connect with the Generation 1 HTU, 
participants had to answer a regular telephone call from a nurse, hang up, activate the HTU, 
and then answer a second call from the nurse using the HTU launch pad. This process 
confused many participants and could be interrupted by other incoming calls. Nurses and 
participants were frustrated that part of many televisits was devoted to connecting and 
other technical issues, rather than to the participants’ clinical and behavioral progress. By 
the end of Phase I, staff said most participants who were still taking part in the intervention 
were able to connect to televisits. Between televisits, IDEATel participants were supposed to 
measure their blood sugar and blood pressure levels and share the information with their 
nurse case manager. With the Generation 1 HTUs, participants shared their measurements 
by uploading the data themselves. According to the nurse case managers interviewed late in 
Phase I, most participants were able to upload their blood pressure and blood glucose 
measurements, and many were able to monitor their clinical data. Sometimes, however, 
participants forgot to perform the upload or inadvertently uploaded the same data multiple 
times—the HTU gave no indication as to when transmission had succeeded.   
Participants could also use the HTU to exchange email with nurse case managers and visit 
the web pages of the American Diabetes Association (ADA). According to the nurses, only 
about half the participants knew how to access email late in Phase I. Although the nurses 
thought about half the participants also knew how to access the ADA web pages, they 
believed few had done so. In addition, Consortium staff reported that few participants had 
used their HTUs to enter behavioral goals (such as for exercise), record their exercise 
activity, or send email to nurse case managers. Consortium staff said that chat rooms were 
never used, with one exception (U.S. Department of Health and Human Services, 2005).  
5.2.1.2 Changes to the Initial HTU Design 
The Consortium tried to increase participants’ proficiency with the HTUs. It developed a 
video tutorial intended to gradually increase participants’ facility, and expected that 
participants would use the HTUs more as their skills grew. However, by the third year of 
the demonstration, staff realized that HTU use was still not increasing. To understand 
participants’ difficulties, an expert on human-machine interactions from Columbia 
University’s Department of BioInformatics analyzed HTU use among a subset of 
participants who enrolled during the second year (Kaufman, Patel et al., 2003; Kaufman, 
Starren et al., 2003). 
Based on the expert’s findings, Consortium staff made several changes. They resolved 
software incompatibilities to increase the user-friendliness of the HTUs’ screens; revised the 
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video tutorial; and, most important, retrained all participants on the use of the HTU. 
Between July 2002 and January 2003, staff were able to train 203 of 359 participants in New 
York City (57 percent) and 350 of 379 in upstate New York (92 percent). The retraining effort 
required the hiring of a new staff member to train some participants in New York City in 
Spanish, and the rehiring of two nurses who originally installed the HTUs in upstate New 
York. In New York City, many participants reportedly were unavailable for this training or 
broke their appointments for it (U.S. Department of Health and Human Services, 2005).  
5.2.1.3 HTU Redesign and Implementation Challenges 
As with Phase I, the Consortium achieved most of its intended improvements with respect 
to the HTU. Unfortunately, most Cohort 1 participants never experienced the 
improvements. The redesigned HTU—the Generation 2—was much smaller and less 
cumbersome than its predecessor. The tabletop unit (pictured in Figure 2) consisted of a 
small flat screen, a large green answer button, a top-mounted camera, a pliable and 
“indestructible” keyboard, and a blood pressure cuff and glucose monitor. The unit featured 
built-in speakers and touch screen technology rather than a stand-alone launch pad. 
In addition to being physically compact, the Generation 2 HTU was meant to be less 
technically demanding of participants. For example, participants connected to televisits 
simply by pressing a green answer button, and automatic data transmission (“data pulling”) 
relieved participants of having to upload glucose and blood pressure readings. Finally, the 
Generation 2 HTUs were supposed to be programmed to turn on automatically at a time of 
the participant’s choosing and ask the participant clinical questions in text format.  
For both technical and financial reasons, newly enrolled Cohort 2 participants did not 
receive HTUs—or any form of intervention—as quickly as they had been told they would. 
Cohort 1 participants had no choice but to continue using their Generation 1 HTUs. Rather 
than wait out the supply shortage, the Consortium and its subcontractor began to design 
another model, the Generation 3 HTU. From the user’s viewpoint, the Generation 3 HTU 
featured the same technical improvements as its immediate predecessor:  simple connection 
to televisits, automatic clinical data uploads, and easy-to-navigate user interface. 
Despite problems with HTU inventory, televisits continued to be the main component of the 
IDEATel intervention during Phase II. Unlike in Phase I, in which intervention teams 
initially sought to have televisits with participants every two weeks, there was no standard 
frequency for televisits during Phase II, according to Consortium staff. Instead, the nurse 
case managers determined an appropriate frequency for each participant in their caseload. 
In both demonstration sites, televisits every four to six weeks was said to be average. 
5.2.1.4 Changed Expectations About HTU Use 
Much of the difficulty with connecting to televisits was resolved in Phase II. The large green 
button on the Generation 2 HTU (or on the screen of the Generation 3 HTU) seemed an 
effective solution for most participants with these models, according to nurse case 
managers. However, some participants who had to keep their Generation 1 HTUs, and even 
a few with the newer models, never overcame their uncertainty about how to connect. 
Nurses reported that 10 to 15 percent of televisits were affected by poor transmission of 
audio or video data or by disconnections. Nurse case managers attributed this problem to 
aging telephone lines. When audio or video was inordinately poor, nurses opted to interact 
with participants by telephone rather than through the HTU. 
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Missed televisits, which had been a concern during Phase I, were not troublingly high 
during Phase II, according to nurse case managers. Except for a small number of 
participants the nurses described as “chronic missers,” others participated in visits unless 
they were away or in the hospital. If participants were less likely to miss visits in Phase II 
than in Phase I, it may simply have been because, as noted, fewer visits were scheduled. 
Participants with Generation 1 HTUs had to upload their stored blood sugar and blood 
pressure readings themselves. The Generation 2 and 3 HTUs, however, were programmed 
to transmit such readings automatically each day with no action by the participant. Nurse 
case managers said the newer procedure worked well, but not perfectly. If participants 
turned off or unplugged their HTUs between televisits, data were not transmitted.  
By the time Phase II began, Consortium staff had drastically lowered their expectations 
about participants’ use of advanced HTU functions, such as visiting the ADA web pages 
and exchanging email with nurse case managers. Access to ADA web pages that had been 
developed for IDEATel was discontinued in November 2003. Thereafter, participants could 
access only ADA pages available to the general public, but the Consortium did not track 
those visits. By that time, staff also tended to downplay the importance of these functions to 
participants’ well-being and motivation for self-care. Nonetheless, the user interfaces of the 
Generation 2 and 3 HTUs were designed to be much easier to navigate than the interface of 
the Generation 1 HTU, which should have facilitated the use of advanced functions. 
According to interviews conducted in 2007, use of advanced functions was as rare in Phase 
II as it had been in Phase I, except for a few participants with prior internet experience. 
5.2.2 HTU learning curves, and frequency and intensity of use 
Cohort 1 members had steeper learning curves than their Cohort 2 counterparts. Since some 
HTU functions were more complex than others, comparing the learning curves in the two 
cohorts may suggest whether the redesign of the HTU resulted in a more user-friendly 
device.  For several HTU functions, Cohort 1 participants took longer than their Cohort 2 
counterparts to use their HTUs for the first time. For example, the median amounts of time 
for monitoring and uploading clinical readings were substantially higher for Cohort 1:  284 
versus 179 days after installation for monitoring, and 19 versus 3 days for uploading 
(Moreno et al., 2005). In contrast, the median time to first measurement of blood sugar or 
blood pressure was the same for both cohorts (1 day), as was the time from HTU installation 
to the first televisit (23 and 21 days, respectively). Note that taking blood pressure and blood 
sugar measurements did not require logging into the HTU, and most participants had been 
using home blood pressure machines and home glucometers before the demonstration 
began. For complex functions, between 6 and 23 percent of Cohort 1 participants had 
learned how to use these functions 12 months after installation. For Cohort 2, these 
percentages ranged from 2 to 7 percent. 
Cohort 1 participants were as likely as Cohort 2 participants to use the basic HTU functions 
during roughly the first 27 months after the start of HTU installation for each phase 
(December 2000 and December 2004). For example, in New York City, virtually all Cohort 1 
participants (99 percent) participated in a televisit at least once during the follow-up period, 
compared with 97 percent among Cohort 2 participants—a difference that is not statistically 
significant. Likewise, in upstate New York, all Cohort 1 and 2 participants attended a 
televisit at least once during the follow-up period. In contrast, use of the complex HTU 
functions was rare for participants in both phases, although Cohort 1 participants in both 
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sites were significantly more likely than their Cohort 2 counterparts to monitor clinical 
readings. Furthermore, Cohort 1 participants were also significantly more likely to read and 
send electronic messages in both sites and to enter behavioral goals in upstate New York. 
These differences are partly explained by the Consortium’s decision to de-emphasize the use 
of complex HTU functions during Phase II, a result of the difficulties participants 
experienced during Phase I (U.S. Department of Health and Human Services, 2005). 
Participants were asked to attend televisits every two weeks (about 24 times a year), and 
more often if necessary (Columbia University, 1998). The intensity of HTU use was higher 
for Cohort 2 than for Cohort 1 participants for five of the eight functions examined, although 
differences were statistically significant for only four (Table 3). For example, in New York 
City, Cohort 2 participants used the televisit function significantly more often than their 
Cohort 1 counterparts—about every 8 and 12 weeks, respectively. The frequency of self-
monitoring recommended to each participant depended on the clinical circumstances and 
was determined by the nurse case managers, with support from the clinical guidelines and 
supervising diabetologists (U.S. Department of Health and Human Services, 2003). 
Likewise, in upstate New York, Cohort 2 participants attended televisits significantly more 
often than their Cohort 1 counterparts—about every five weeks versus every seven, 
respectively. Furthermore, in both sites, Cohort 2 participants measured their blood sugar 
and blood pressure significantly more often than Cohort 1 participants. Because of the data-
pulling feature of the Generation 2 and 3 HTUs, Cohort 2 participants in both sites uploaded 
their blood pressure and blood sugar readings between seven and nine times more often, on 
average, than their Cohort 1 counterparts. For the complex functions, such as monitoring 
clinical readings, the between-cohort differences in the average frequency of use of HTU 
functions were small and not statistically significant.  
 
 
HTU Function 
 
Cohort 1 
 
Cohort 2 
Difference 
(p-Valuea) 
Basic Functions 
Measure Blood Sugar    
New York City 161.1 208.6  47.5 
(.048) 
Upstate New York 
 
237.0 386.2 149.2 
(.000) 
Measure Blood Pressure    
New York City 147.4 199.1  51.7 
(.013) 
Upstate New York 163.8 245.6  81.8 
(.000) 
Complex Functions 
Upload Clinical Readings    
New York City 9.3 128.5  119.2 
(.000) 
Upstate New York 14.7 169.4  154.7 
(.000) 
Monitor Clinical Readings    
New York City 5.5 6.8 1.3 
(.697) 
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HTU Function 
 
Cohort 1 
 
Cohort 2 
Difference 
(p-Valuea) 
Upstate New York 
 
8.7 6.7 – 2.0 
(.737) 
Participate in Televisits    
New York City 4.5 6.4 1.9 
(.000) 
Upstate New York 7.0 10.5  3.5 
(.000) 
Read Electronic Messages    
New York City 2.1 0.5 – 1.6 
(.869) 
Upstate New York 4.8 3.1 – 1.7 
(.878) 
Send Electronic Messages    
New York City 1.1 0.5 – 0.6 
(.897) 
Upstate New York 1.5 1.3 – 0.2 
(.893) 
Enter Behavioral Goals    
New York City 3.0 0.6 – 2.4 
(.806) 
Upstate New York 1.6 1.5 – 0.1 
(.503) 
Sample Sizeb 753 230 – 
 
Source: IDEATel database on HTU use linked to the IDEATel tracking status file (Columbia 
University, 2007a, 2007b).   
Notes: Estimates weighted based on length of enrollment between HTU installation and the dropout 
date or the cutoff date (February 15, 2003, for Cohort 1 and February 27, 2007, for Cohort 2). In 
Cohort 1, most participants used only Generation 1 HTUs; in Cohort 2, 226 participants used 
Generation 2 HTUs and 4 used Generation 1 HTUs. Excludes results for the following 
functions because no Cohort 2 participants used them: consult American Diabetes Association 
web pages, enter medications, and enter exercise activities. 
aControlling for participants’ characteristics at baseline. 
bThe sample size varies by site and function. 
HTU = home telemedicine unit. 
Table 3. Mean Annual Number of Times HTU Function Was Used During the Intervention, 
by Cohort and Size  
Cohort 1 participants used more functions than Cohort 2 participants (Table 4). In New York 
City, Cohort 1 participants used 4.3 HTU functions, on average, compared with 2.5 
functions for Cohort 2. The averages for upstate New York are very similar (4.5 and 2.7, 
respectively). As noted, these differences are partly explained by the Consortium’s decision 
to de-emphasize the use of complex HTU functions in Phase II due to the difficulties 
experienced in Phase I. Furthermore, by the end of the follow-up period, none of the Cohort 
2 participants in both sites had used all the functions, though between 2 and 6 percent of 
Cohort 1 participants (New York City and upstate, respectively) had used all of them. 
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Cohort 2 participants in both sites had longer televisits, on average, than their Cohort 1 
counterparts. In New York City, the average duration of a Cohort 2 televisit (29 minutes) 
was significantly higher, by about 5 minutes, than the Cohort 1 average. In the upstate site, 
the difference in the average duration of a televisit was smaller (about 2 minutes), but still 
significantly (statistically) longer for Cohort 2 participants relative to their Cohort 1 
counterparts (33 and 31 minutes, respectively).  
 
 
HTU Function 
 
Cohort 1 
 
Cohort 2 
Difference 
(p-Valuea) 
Any Function (Percentage)b    
New York City 99.6 99.3 – 0.3 
(.602) 
Upstate New York 100.0 99.9 – 0.1 
(.580) 
All HTU Functions (Percentage)b    
New York City 2.4 0.0 – 2.4 
(.233) 
Upstate New York 5.7 0.0 – 5.7 
(.017) 
Number of Functions Used b    
New York City 4.3 2.5 – 1.8 
(.000) 
Upstate New York 4.5 2.7 – 1.8 
(.000) 
Average Duration of Televisits 
(Minutes)c 
   
New York City 24.3 29.4 5.1 
(.000) 
Upstate New York 31.2 33.0 1.8 
(.004) 
Sample Sized 753 230 – 
 
Source: IDEATel database on HTU use linked to the IDEATel tracking status file (Columbia 
University, 2007a, 2007b).  
Notes: Estimates weighted based on length of enrollment between HTU installation and the dropout 
date or the cutoff date (February 15, 2003, for Cohort 1 participants and February 27, 2007, for 
Cohort 2 participants). In Cohort 1, most participants used only Generation 1 HTUs; in Cohort 
2, 226 participants used Generation 2 HTUs and 4 used Generation 1 HTUs. 
a Controlling for participants’ characteristics at baseline.  
bExcludes measurement of blood pressure and measurement of blood sugar, as neither function 
required system log-in. Also excludes consultations of American Diabetes Association web pages, 
because the Consortium did not collect data on these consultations after November 13, 2003. 
cThe number of participants participating in televisits varies by function. 
d The sample size varies by site. 
HTU = home telemedicine unit. 
Table 4. Patterns of HTU Use During the Intervention, by Cohort and Site 
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The analysis of HTU use for Cohort 1 and Cohort 2 participants has four limitations. First, 
without a suitable control group to account for secular trends against which to compare 
changes in use in both cohorts, it is not possible to determine whether the redesign of the 
HTU is the sole factor behind the higher use by Cohort 2 participants of the array of HTU 
functions. Second, because communications between participants and providers are 
confidential, Mathematica was unable to determine whether any instances of HTU use were 
self-initiated or whether they occurred only after reminders from nurse case managers 
during televisits or in electronic messages. Furthermore, the use of the data-pulling feature 
in Generation 2 HTUs could have changed Cohort 2 participants’ use of other functions by 
relieving them of the need to upload their glucose and blood pressure readings between 
televisits. Thus, it is unclear how much effort Consortium staff expended to generate the 
levels of use observed and how this varied by HTU type and cohort. Third, the sample size 
for Cohort 2 participants was small. Thus, it is likely that the estimates from this group are 
less robust than the estimates for the Cohort 1 sample. Finally, the Consortium stopped 
collecting data on use of the ADA web pages—an important intervention component—in 
November 2003. Therefore, it is not possible to assess the extent to which participants in 
both phases used these educational materials, particularly after Cohort 1 participants were 
retrained on HTU use during the third year of the demonstration. 
5.3 Intermediate clinical outcomes 
The intervention had substantial, statistically significant favorable impacts on blood sugar 
control and lipid levels in both demonstration sites. In New York City and upstate, blood 
sugar control was better in the treatment group than in the control group, and total 
cholesterol levels were about 5 to 6 percent lower, on average (Figure 3). In the upstate site 
only, the improvement in blood sugar control was greater for participants with poorly 
controlled blood sugar at baseline than it was for others. The intervention also affected in-
person blood pressure measurements, but more so upstate. In New York City, mean systolic 
and diastolic readings were 2 percent lower in the treatment group than in the control 
group, although the difference was not statistically significant. Upstate, the mean differences 
were about 3 percent and were highly significant.  
Although the Consortium prespecified blood sugar, blood pressure control, and lipid levels 
as the main study outcomes, it collected data on several other clinically important outcomes. 
According to our analysis, IDEATel did not affect ratios of microalbumin to creatinine (an 
indicator of kidney damage from diabetes), 24-hour ambulatory blood pressure 
measurements, body mass index, overweight or obesity, waist-to-hip ratio, or abdominal 
girth in either site. In addition, the intervention had no effects on mortality. 
The attrition rate was high in both sites, especially among treatment group members (about 
23 percent in New York City and 16 percent upstate between baseline and year 1). The 
substantial attrition rate among enrollees poses two serious problems. First, the reduction in 
sample size limits the power to detect impacts. For example, for a single comparison of 
treatment and control group means, the 30 percent loss of sample in the New York City site 
would result in minimum detectable differences (MDDs) roughly 25 percent greater than for 
the full sample, while the 58 percent loss of sample in the upstate site would increase the 
MDDs by about one-third. Second, and perhaps more important, depending on the 
mechanism for attrition, impacts calculated only on enrollees who remain in the study could 
be biased. Bias can occur if the dropout rate of enrollees with unmeasured characteristics 
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that predict outcomes (for example, motivation or psychological distress) is greater in one 
intervention group than the other. Such differential dropout threatens the benefits of 
random assignment. Differential dropout cannot be directly ascertained. However, an 
examination of the recorded reasons for enrollee dropout and the characteristics of enrollees 
who dropped out, as well as sensitivity tests consisting of imputed possible values of 
outcome variables for those who dropped out surprisingly suggested no likelihood of bias. 
5.4 Medicare service use and costs 
IDEATel had no effects on treatment group members’ use of Medicare-covered hospital, 
skilled nursing facility, or physician services. Upstate, however, use of home health care was 
statistically significantly higher for treatment group enrollees than for their control group 
counterparts. It also did not affect receipt of dilated eye examination, hemoglobin A1c 
testing, low-density lipoprotein testing, and urine microalbumin testing.   
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Source: IDEATel annual in-person interviews, conducted from December 2000 through October 2006 
(Columbia University, 2007d). 
*,**,*** Indicate treatment-control difference is statistically significant at the .05, .01, or .001 level, 
respectively. 
Fig. 3. Impacts of IDEATel on Cohort 1 Enrollees’ Selected Key Clinical and Laboratory 
Outcomes, Baseline to Year 4 
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The mean annual Medicare expenditures were higher for treatment group members than for 
control group members in both sites, but the differences were not statistically significant 
(Table 5). In New York City, the mean annual Medicare expenditures were $13,845 in the 
treatment group and $12,961 in the control group. Upstate, mean annual expenditures were 
$9,566 in the treatment group and $8,450 in the control group. By service type, statistically 
significant treatment-control differences were few. However, treatment group members had 
higher expenditures in all service categories except physician office visits, outpatient 
hospital, and laboratory services in New York City. 
 
 New York City Upstate New York 
Component/Service
Treatment
Group 
Control
Group 
Difference
(p-Value) 
Treatment 
Group 
Control 
Group 
Difference 
(p-Value) 
Cohort 1 (Both Phases) 
Total Expenditures 
for Medicare-
Covered Services 
$13,845 $12,961 
$884 
(.476) 
$9,566 $8,450 
$1,116 
(.094) 
Total Intervention- 
Related Costsa 
$8,662 0 n.a. $8,662 0 n.a. 
Total Costs $22,507 $12,961 
$9,546 
(.001) 
$18,228 $8,450 
$9,778 
(.000) 
Cohort 2 (Only Phase II) 
Total Expenditures 
for Medicare-
Covered Services 
$11,906 $11,661 
$245 
(.931) 
$6,450 $8,694 
- $2,244 
(.132) 
Total Intervention- 
Related Costs 
$8,437 0 n.a. $8,437 0 n.a. 
Total Costs $20,343 $11,661 
$8,682 
(.000) 
$14,877 $8,694 
$ 6,183 
(.000) 
Cohort 1 Sample 
Size 
379 358 - 446 442 - 
Cohort 2 Sample 
Size 
82 84 - 161 164 - 
aTotal demonstration service costs for Cohort 1 are based on the arithmetic average of demonstration 
costs for Phase I and Phase II, weighted by the average length of time that Phase I participants were 
enrolled during each phase. 
n.a. = not applicable. 
Table 5. Estimated Annual Per-Person Expenditures for Medicare-Covered Services, 
Demonstration Costs, and Total Costs 
5.5 Demonstration costs 
We estimated that the IDEATel intervention cost about $34.8 million or about 61 percent of 
the total demonstration budget. Depending on the study phase, between 11 and 15 percent 
of the total budget was for intervention design; between 46 and 50 percent was for 
implementation; and less than 1 percent was for closeout (for example, deinstalling HTUs 
when participants disenrolled or died). For Phase I, implementation costs ($12,905,572) 
divided by the number of treatment group enrollees (844) over the length of the intervention 
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(2 years) provides an estimate of the annual implementation cost per participant, or $7,645. 
For Phase II, implementation costs  ($14,338,429) divided by the number of treatment group 
enrollees (514 treatment group members from Cohort 1 who were still participating in the 
demonstration at the beginning of Phase II [February 2004], and all 249 Cohort 2 treatment 
group members), gives a per-participant cost estimate of $7,029. To calculate the total annual 
costs per participant per cohort, the analysis assumed that Phase I lasted two years, as stated 
in the Consortium’s original proposal, and that Phase II lasted an average of 2.67 years 
(three years for Cohort 1 and two years for Cohort 2 [Columbia University, 1998]).  Design 
and closeout costs were depreciated over four years for Cohort 1 and over three years for 
Cohort 2 (U.S. Department of Health and Human Services, 2005). The final cost per 
participant is $8,662 for Cohort 1 (both phases), and $8,437 for Cohort 2 (only Phase II). 
When the intervention’s annual cost per participant is added to the annual Medicare 
expenditures of treatment group members, the treatment group’s costs are about two and 
one-half times larger than the control group’s costs. Thus, based on experiences of enrollees 
through December 2003, the demonstration substantially increases total costs. Even if the 
intervention had eliminated the treatment group’s need for all other Medicare expenditures, 
that group’s costs would have exceeded the control group’s costs (upstate) or be within 5 
percent of these costs (New York City). 
5.6 Summary of findings 
The IDEATel demonstration met Congressional implementation requirements. However, 
the intervention as delivered was neither as intensive nor as technologically sophisticated as 
originally designed, since the Consortium encountered unexpected challenges and 
deliberately departed from its plans in some areas. Had the Consortium retained its original 
target to hold televisits every two weeks with all participants―the most popular component 
of the intervention―participants might have been more motivated to use their HTUs and 
interact more frequently with their nurse case managers. In addition, this would have 
allowed nurse case managers to provide more guidance to participants on using other HTU 
functions, such as setting behavioral goals, which might have resulted in better clinical 
outcomes. Similarly, had the redesigned HTU been cheaper and less sophisticated, 
participants‘ acceptance of this technology might have  increased and the costs of the 
demonstration might have been more reasonable. 
IDEATel was clinically effective over the medium term in only one of two sites, which made 
it difficult to determine why it was more effective among participants upstate than in New 
York City or whether some demonstration features are essential for long-term impacts. The 
expectation that the demonstration could generate offsetting savings for Medicare services 
did not materialize, in spite of the six-year follow-up. The main driver of these costs was the 
size of the cooperative agreement allocated to the demonstration’s operations, compounded 
with the use of very expensive HTUs. Table 6 summarizes the key findings from the 
evaluation of IDEATel.  
While an ongoing program similar to IDEATel could potentially have lower costs, it would 
be virtually impossible for such a program to generate cost savings, particularly because the 
intervention-related costs of the demonstration were excessive by any standard. Given the 
absence of effects on costs or services, however, even a less expensive version of this 
demonstration would not produce sufficient Medicare savings to offset demonstration costs. 
Furthermore, while IDEATel had clinical impacts similar to those of other interventions for 
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individuals with diabetes, it cost far more. For instance, Project Dulce (a diabetes case-
management and self-management training program) had clinical impacts (derived from a 
comparison of program participants to a matched control group) similar in size to those 
produced by IDEATel. While the program was cost-effective according to commonly 
accepted standards, Project Dulce cost an estimated $662 to $1,537 per participant per year 
to implement—about an eighth the cost of IDEATel (Gilmer et al., 2007).  
In sum, the results are clear: the IDEATel program cannot be cost neutral, given its large 
costs and the complete absence of any savings in traditional Medicare costs for 
hospitalizations and other covered services. Even if costs were halved and the intervention 
reduced hospitalizations by 50 percent (both highly unlikely scenarios), the program would 
still increase total costs to the government. 
 
Outcome New York City Upstate 
Implementation Analysis 
HTU Use 
Cohort 1: Declined rapidly  
Cohort 2: Declined rapidly  
Cohort 1: Constant through 2003, but 
declined thereafter 
Cohort 2: Declined rapidly  
Impact Analysis 
Communication 
with Providers 
and Patient 
Self-Care 
Cohort 1: Large positive impactsa 
Cohort 2: Large positive impacts in 
year 1 
Cohort 1: Large positive impactsa 
Cohort 2: Large positive impacts in 
year 1 
Clinical 
Outcomes 
Cohort 1: Little or no impacta 
Cohort 2: No significant impacts in 
year 1 
Cohort 1: Large and sustained 
impactsa 
Cohort 2: No significant impacts in 
year 1 
Service Use and 
Expenditures 
Cohort 1: No Medicare savings in 
any year except year 3 
No effects on hospitalizations or 
service use, for either cohort 
Cohort 1: No Medicare savings in 
any year  
No effects on hospitalizations or 
service use, for either cohort 
Total 
Medicare 
Costs 
The demonstration’s high costs ($8,662 per participant per year for Cohort 
1 and $8,437 per participant per year for Cohort 2) were not offset by any 
savings in Medicare Part A or Part B expenditures 
a Findings are for all four years for which follow-up survey data were available. 
Table 6. Summary of Findings by Site 
6. Discussion 
6.1 Implications of the IDEATel evaluation for home-based telemedicine  
Mathematica’s overall findings about IDEATel are consistent with those from a CBO review 
of disease management programs for diabetes in which clinical improvements were not 
associated with long-run reduced costs (implied to be over a time frame of at least one year) 
(Congressional Budget Office, 2004). They are not consistent, however, with findings from a 
commercial diabetes management program that seemed to yield clinical improvements and 
cost savings in one year’s time (Piette et al., 2001;Villagra & Ahmed, 2004). Because the 
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CBO-reviewed studies and the Villagra-Ahmed study rely on evaluation designs of different 
credibility and robustness, the above findings should be interpreted cautiously. 
What mechanisms might have produced the modestly improved clinical outcomes? By 
providing participants free blood sugar and blood pressure meters, nurse case managers to 
encourage use of these meters, and a means of uploading the meter readings, the 
intervention set the stage for timely and aggressive treatment of diabetes symptoms. 
Specifically, the nurses conveyed concerns to supervising diabetologists. These physicians 
suggested different doses of guideline-recommended prescription drugs to participants’ 
primary care physicians, who made the changes and participants responded favorably.   
The problems with the HTU suggest that IDEATel’s positive clinical effects may have been 
due more to the nurses’ telephonic interactions with the patients than to the expensive HTU 
equipment. The intervention as implemented had limited acceptability among participants. 
For example, many participants found the HTU used during Phase I of the demonstration 
somewhat unappealing. In addition, participants found the HTU cumbersome or physically 
imposing (5 and 28 percent of Cohort 1 treatment group members refused installation 
between baseline and year 4 in New York City and upstate New York, respectively). They 
also found the more advanced functions difficult to perform (4 and 5 percent of Cohort 1 
treatment group members left the study citing difficulty with the HTU between baseline and 
year 4 in New York City and upstate New York, respectively).  
Although demonstration staff said participants who attended televisits enjoyed interacting 
with nurse case managers, participants attended televisits much less often than the 
Consortium requested (especially in New York City). Technical difficulties may have made 
the HTU more of a distraction than an asset for purposes of case management. As noted in 
section 4, the evaluation cannot definitively attribute the intervention’s positive impacts to 
using the HTU, interacting with nurse case managers, or both because the demonstration 
was not designed to measure each component’s marginal benefits. Nonetheless, these 
problems with the HTU suggest that this expensive component of the intervention may not 
have been the essential factor for producing the favorable effects on clinical indicators. 
The finding that the intervention did not affect participants’ use of Medicare-covered 
services, including diabetes-specific preventive services, was disappointing to program 
operators, but perhaps was not altogether surprising. First, televisits were not meant to 
substitute for regular physician visits, so no savings were expected in visits. Second, the 
provision of free annual hemoglobin A1c, lipid, and urine microalbuminuria testing to both 
the treatment and control groups during annual assessments would have blunted any 
between-group differences that might have arisen for these outcomes. It may also have 
attenuated effects on hospital use had these tests not been conducted for the control group 
absent the demonstration (to the extent that knowledge of problems with such indicators 
could lead to behavior or treatment changes that would ward off such exacerbations). Third, 
the demonstration’s duration for Cohort 1 may have been too short to detectably reduce the 
need for hospitalizations or other health service use through the prevention of heart attacks, 
stroke, kidney failure, eye damage, and other complications. Fourth, enrollees may not have 
been at high risk for costly hospitalizations. Baseline hemoglobin A1c, lipid, and blood 
pressure levels suggested that enrollees were relatively well controlled in the three 
measures. 
It is slightly disappointing that the intervention did not affect receipt of dilated eye exams; 
between 87 and 95 percent of control group enrollees received them, compared to between 
88 and 98 percent of treatment group enrollees (in upstate New York and New York City, 
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respectively). One would expect IDEATel nurse case managers to remind participants to 
have the exam, a widely accepted component of diabetes treatment guidelines. While nurses 
may have neglected to make reminders because they faced competing priorities during 
televisits or their case management software was not programmed to issue such reminders, 
this would not excuse such omission from their interactions. It could also be that 
participants ignored reminders, but this would suggest that the nurses were unsuccessful in 
developing enough trust and rapport with participants to encourage at least some of them to 
have this important exam. Baseline rates were also fairly high; perhaps physicians willing to 
participte in the study were already providing high quality care and beneficiaries willing to 
enroll were already adherent to recommended care. It may have thus been difficult for the 
intervention to effect substantial additional improvements above the already high baseline 
rates. 
Given the absence of effects on service use, finding no effects on Medicare costs was not 
surprising. The higher Medicare expenditures for the treatment group may have been 
strictly a chance difference or may be because IDEATel identified the need for some health 
services among medically underserved beneficiaries. The expectation that the demonstration 
could generate offsetting savings for Medicare services did not materialize, in spite of the 
six-year follow-up. The main driver of these costs was the size of the cooperative agreement 
allocated to the demonstration’s operations, compounded with the use of very expensive 
HTUs. 
6.2 Potential role of home telemedicine in the Medicare program 
Although the promise of home telemedicine has long been recognized by experts and 
policymakers, its use in the U.S. health care system is far from widespread, particularly in 
the Medicare program, the largest health insurer in the U.S. There are several studies that 
show that home telemedicine for Medicare can be efficacious, but they are limited by small 
sample sizes, inadequate length of follow-up, and inconclusive results (Hersh et al., 2006). 
Consequently, the failure of the IDEATel demonstration to provide a conclusive assessment 
of the potential of home telemedicine―improve access to care for Medicare beneficiaries 
with chronic conditions, provide cost-effective care to the Medicare population, and 
generate cost savings for the Medicare program―was disappointing for those  expecting 
such changes in outcomes, such as the Agency for Healthcare Research and Quality, which 
sponsors a periodic systematic review of the effects of telemedicine for Medicare 
beneficiaries. Furthermore, in early 2008, at the end of the demonstration, the optimism 
among program developers, implementers, health care providers, and policymakers about 
whether and how home telemedicine could play a role in the Medicare program seemed to 
be fading away. This resulted primarily from the shift in emphasis from telemedicine to 
electronic health records that the federal government adopted starting in 2004. 
A turnaround point for this impasse was the largest legislative push on health information 
technology (IT) ever in the U.S. In 2009, recognizing the unrealized potential of health IT to 
improve the quality and delivery of health care, Congress passed the Health Information 
Technology for Economic and Clinical Health (HITECH) Act as part of the American 
Recovery and Reinvestment Act. The goal of HITECH is to promote the adoption of health 
IT in public insurance programs, including the potential use of home telemedicine in 
Medicare to support key principles of the patient-centered medical home to improve health 
care quality and efficiency (Moreno et al., 2010). Recent health reform legislation (Patient 
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Protection and Affordable Health Care Act [P.L. 111-148]) offers promising prospects for 
home telemedicine, including an Innovation Center within CMS, the agency of the U.S. 
Department of Health and Human Services that administers Medicare. This center will test, 
evaluate, and expand in Medicare (as well as in Medicaid and the Children‘s Health 
Insurance Program) different payment structures and methodologies to reduce program 
expenditures while maintaining or improving quality of care, a role that telemedicine could 
fulfill. Other mandates of the health reform legislation that could directly or indirectly 
facilitate the adoption of home telemedicine in the program include a Federal Coordinated 
Health Care Office within CMS. The mission of this office is to more effectively integrate 
Medicare and Medicaid benefits and improve coordination between the federal government 
and states in order to improve access to and quality of care and services for dual-eligible 
beneficiaries (that is, those eligible for both Medicare and Medicaid), who typically have 
many care-coordination needs. There are many other health-reform legislative dispositions 
that could influence the adoption and use of home telemedicine, but we do not discuss them 
here because they are in early stages of development and implementation. 
In sum, HITECH, the health-reform legislation, and other pre-HITECH legislation are 
intertwined and highly relevant to home telemedicine in the Medicare program. Despite our 
finding that IDEATel was unlikely to be cost-effective given that the demonstraton had 
modest clinical impacts at excessive cost, the concept of home telemedicine is still 
promising. One of the factors that has greatly enhanced the prospects of home telemedicine 
is the continous decline in health IT prices, such as those for smartphones, personal digital 
assistants, intelligent devices, and web-based applications. This unique alignment of policies 
and affordable technology raises hopes that there can be positive synergies in the immediate 
future to build a solid basis for home telemedicine in the Medicare program.  
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